Multiple subconjunctival bevacizumab for advanced primary pterygium.
Effectiveness of multiple subconjunctival bevacizumab injections in advanced primary pterygium was studied the first time. Treatment produced regression of pteryium and improvement of best-corrected visual acuity from 20/100 to 20/60 at 6-mont follow-up. Off-label short-term use of sbconjunctival bevaciumab is effective.
Department of Ophthalmology, CSM Medical University, Lucknow, 226018, India. sandeepsaxena2020@yahoo.com
Sandeep
S
Saxena
Kuldeep
K
Vishwkarma
Mohit
M
Khattri
Poonam
P
Kishore
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D006801:Humans; D007267:Injections; D008297:Male; D011625:Pterygium / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000188:drug therapy / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab